A Quality of Life Study in Patients With Migraines
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00298805
Recruitment Status :
(Study terminated due to expiration of IRB approval)
The purpose of this study is to compare depressive characteristics in migraine patients to those observed in patients with epilepsy in a previous study, and determine whether those symptoms are unique to patients with epilepsy.
Condition or disease
A form of depression known as dysphoric-like disorder is common in people with epilepsy, which may significantly affect the quality of life in these people, as shown in a previous study. However, it is unclear if this depressive disorder is unique to patients with epilepsy. In order to assess whether these symptoms are unique and idiosyncratic to the epilepsy population, in this multi-center study, these dysphoric depressive features will be contrasted to those seen in patients with other neurologic or psychiatric conditions. Migraine is selected as one of the comparison disorders because it shares with epilepsy characteristics of being a recurrent episodic central nervous system disorder, and our site will only enroll patients with migraine headaches.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Migraine patients will be recruited from the outpatient neurology clinics / offices.
Male or female 18 years of age or older
Have the diagnosis of migraine
Have had no change in migraine medication(s) 30 days prior to study
Achieve a satisfactory score on the Wide Range Achievement Test 3 (WRAT3) test at the screening visit
Capable of completing self-reporting questionnaires
Willing and able to provide written informed consent and comply with the study protocol
Presence of a clinically significant comorbidity of an unstable or progressive nature
Presence of major depression
Participation in an investigational drug study within the past 30 days
Inability to communicate well with site study personnel